Something Phishy at Pfizer... or just trade as usual.. A massive run up on the stock prices, then trade falls after he sells?? Stocks are not my forte but something is fishy here..

By Shalini Nagarajan
Nov. 11, 2020, 10:21 AM

Pfizer CEO Albert Bourla sold 62% of his stock in the company on the same day the drugmaker announced the results of its COVID-19 vaccine trial.

Bourla sold $5.6 million in stock on Monday as part of a predetermined trading plan adopted August 19.

His stock sale was carried out at $41.94 a share. The 52-week-high for Pfizer stock is $41.99, which means the CEO cashed out his shares at close to their highest price this year.

Pfizer and its German partner BioNTech on Monday became the first to post positive results from late-stage COVID-19 vaccine trials.

Pfizer CEO Albert Bourla sold 62% of his stock on the same day the company announced its experimental COVID-19 vaccine succeeded in clinical trials.

The vaccine announcement sent Pfizer's shares soaring almost 15% on the day.

Bourla sold 132,508 shares in the company at an average price of $41.94 a share, or $5.6 million total, according to filings registered with the Securities and Exchange Commission. The 52-week high for Pfizer's stock is $41.99, meaning Bourla sold his stock at almost its highest value in the past year.

His stock sale was carried out through a routine Rule 10b5-1, a predetermined trading plan that allows company staff members to sell their stock in line with insider-trading laws. Bourla's sale was part of a plan adopted August 19, the filing showed. He continues to own 81,812 Pfizer shares.